Analyst: Lilly doesn't overshadow semaglutide in spite of strong data

On Thursday, US pharmaceutical firm Eli Lilly has presented convincing data in favor of the drug candidate tirzepatide, which is a GLP-1 analog.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst emphasizes 2021 guidance in Genmab fiscal report
For subscribers